Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
about
A preliminary study of skin ultrasound in diffuse cutaneous systemic sclerosis: Does skin echogenicity matter?Skin imaging in systemic sclerosis.Patient-reported outcome assessment in vasculitis may provide important data and a unique perspectiveReliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosisTwenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosisMinimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studySubmaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testItems for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseReliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisClinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisThe symptom burden index: development and initial findings from use with patients with systemic sclerosis.Development of a provisional core set of response measures for clinical trials of systemic sclerosis.Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trialNew directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).Biomarkers in systemic sclerosis.Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells.The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisPoints to consider for designing trials in systemic sclerosis patients with arthritic involvement.Points to consider in renal involvement in systemic sclerosis.Muscle involvement in systemic sclerosis: points to consider in clinical trials.Assessment of skin involvement in systemic sclerosis.A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis.
P2860
Q30359351-86DB4FFE-35A4-407C-9A20-18B2378E832AQ30372810-DBA83219-D12D-477D-8444-8F2378B80D78Q33607935-80196152-F9B0-4C4F-BB90-5CD4F81F1DAAQ34109827-40A0FB65-C0E7-4C40-A696-55B6EEAF28EBQ34727670-BAE0F83B-1632-411D-8B0E-05117C66E0DCQ34979209-EA62062C-5803-4284-B90F-7153D30A83BCQ35638054-3C5AFA64-AAFE-4824-9FAD-406A842DBB8FQ35638700-5F14032F-B44F-4442-B5D8-C5DB6AB649E7Q35784089-3AD4BF79-24A8-4968-BB56-DD9F8C725598Q35851777-319622BA-33FE-4E20-AF91-1CA8F8F384C5Q35977294-B2805226-6090-4676-8577-39D72A206576Q36175068-8ABC5F11-86CE-4528-BFDF-C7F720808165Q36758822-3F3E3E39-5500-4F04-9AFF-12362F70140EQ37460765-6E92CD41-CD2D-48D1-8CE6-7B6788D3530CQ37460792-2DDB7DA5-D5A7-40CC-8C45-6213E42FB6C2Q37460808-0E020DED-FC7C-4B55-B5A6-F82024F73D75Q37586400-B6A98E7D-9BDE-48CF-9FAE-6F84BC7A0172Q37730018-E797B13A-237D-4F9A-B2BA-2F779A97EE07Q39322803-9F5534E2-72E2-42AB-819C-B6CFF8EF0E5CQ40002833-F891C425-BF85-40FA-A2BE-5C390B5C45EAQ45938471-07A48123-0F3A-43FB-B1EC-80BE46950FE7Q45995241-43F0A645-D2C6-4F93-A330-C8D03B48D1A6Q46256178-1A416930-D9F6-4835-A3E9-3ABC0347ABDCQ47835767-348ADCFE-8172-47FD-934D-D016E903E16EQ49860214-5CEB99B3-C480-4565-AB62-F280DA75364FQ52374296-47B07D75-D56E-4A19-8EF2-4D3F264CF507
P2860
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@ast
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@en
type
label
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@ast
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@en
prefLabel
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@ast
Current status of outcome meas ...... erosis. Report from OMERACT 6.
@en
P2093
P1476
Current status of outcome meas ...... lerosis. Report from OMERACT 6
@en
P2093
Daniel E Furst
Gabriele Valentini
Maria E Suarez-Almazor
Peter A Merkel
Philip J Clements
P304
P407
P577
2003-07-01T00:00:00Z